12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD0424: Phase I started

Cancer Research U.K. (London, U.K) began an open-label, U.K. Phase I trial of once-daily oral AZD0424 from AstraZeneca for 28 days in about 96 patients. The dose-escalation Phase Ia portion will evaluate AZD0424 alone and with combination agents, while the Phase Ib...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >